Eli Lilly and Company has entered into a definitive agreement to acquire Versanis, a New York City-based biopharmaceutical company focused on the treatment of cardiometabolic disease, for up to $1.93 billion.Versanis’ leading asset, bimagrumab, is presently being evaluated in a BELIEVE Phase 2b clinical trial for the treatment of obesity both on its own and […]